Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs MKS Instruments (MKSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs MKS Instruments — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while MKS Instruments trades at $230.19 (market cap $16.74B). The key difference: MKS Instruments is the larger of the two by market cap, and MKS Instruments pays a 0.4% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and MKS Instruments for 9 Days on average.
| KYMR | MKSI | |
|---|---|---|
Market Cap | $8.87B | $16.74B |
Volume | 779,107 | 1,685,097 |
Sector | Health | Technology |
52-Week High | $127.31 | $444.80 |
52-Week Low | $55.80 | $134.42 |
Typical Hold Time | 0 Days | 9 Days |
Enterprise Value | $8.26B | $20.31B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MKSI trades at $247.56, down 0.94% on the day, with a bearish technical signal despite strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $3.30 exceeding expectations by 13.4%. Revenue growth continues with 2026 projections showing $4.3B and net profit margin expanding to 10.09%. Analyst consensus remains strongly bullish with 82.8% buy ratings and a $404 price target representing 63% upside potential.
The stock presents compelling growth potential driven by earnings momentum and institutional confidence, though near-term technical weakness and margin pressures from facility expansions pose risks. Long-term wafer fabrication equipment demand and ESG initiatives provide strategic tailwinds, but investors should monitor execution on profitability targets amid competitive pressures in the electronics sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About MKS Instruments
MKS develops instruments, systems, and process control solutions for advanced manufacturing. Its technologies serve semiconductor manufacturing, electronics and packaging, photonics, and specialty industrial applications.
Read more on MKSI →
